Lumos Pharma, Inc.
Lumos Pharma, Inc. (LUMO) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
lumo · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Lumos Pharma, Inc.You LUMO | $38M | N/A | — | — |
 Cerecor Inc. CERC | $39M | N/A | — | -$5.84 |
 Eyenovia, Inc. EYEN | $39M | N/A | — | $0.00 |
 Grace Therapeutics, Inc. GRCE | $37M | N/A | — | -$1.13 |
 Opus Genetics, Inc. IRD | $330M | N/A | — | -$0.08 |
 LianBio LIANY | $12M | 2.11x | — | $0.05 |
 Magenta Therapeutics, Inc. MGTA | $42M | N/A | — | $0.00 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Lumos Pharma, Inc. (LUMO) measures how much investors pay for each dollar of the company's trailing earnings. LUMO's current PE ratio of N/A is calculated by dividing its stock price of $4.34 by its TTM earnings per share of —.
Frequently asked questions
LUMO pe ratio · 6 questionsLUMO's current PE ratio is N/A as of 2026-06-09, based on a stock price of $4.34 and TTM EPS of —. Data sourced from Financial Modeling Prep via LUMO's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Lumos Pharma, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09